Merck (MRK) Misses Q4 EPS by 9c; misses on outlook

Merck (NYSE: MRK) reported Q4 EPS of $1.72, $0.09 worse than the analyst estimate of $1.81. Revenue for the quarter came in at $15.6 billion versus the consensus estimate of $15.47 billion.

GUIDANCE:

Merck sees FY2025 EPS of $8.88-$9.03, versus the consensus of $9.21. Merck sees FY2025 revenue of $64.1-65.6 billion, versus the consensus of $67.36 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Daiwa Securities Upgrades HP Enterprise (HPE) to Outperform (2)
• Barclays Upgrades Universal Music Group NV (UMG:NA) (UMGNF) to Overweight
• McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance